Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce
anti-inflammatory type II monocyte development during treatment of MS, and if these antigen
presenting cells (APC) will promote Th2 and Treg differentiation of naïve T cells.
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
National Multiple Sclerosis Society Teva Neuroscience, Inc.